Warning: Declaration of subscribe2_widget::addPluginSubMenu() should be compatible with mijnpress_plugin_framework::addPluginSubMenu($title, $function, $file, $capability = 10, $where = 'plugins.ph...') in /data/32/2/10/97/2499423/user/2737425/htdocs/wordpress1/wp-content/plugins/subscribe2-widget/subscribe2-widget.php on line 18

Warning: Declaration of subscribe2_widget::addPluginContent($links, $file) should be compatible with mijnpress_plugin_framework::addPluginContent($filename, $links, $file, $config_url = NULL) in /data/32/2/10/97/2499423/user/2737425/htdocs/wordpress1/wp-content/plugins/subscribe2-widget/subscribe2-widget.php on line 18
Uncategorized | SEBIO

Medical device firm Contego Medical lands $22.3M from investors

Posted by on Jan 14, 2020 in Newsroom, Uncategorized | 0 comments

RALEIGH, N.C. – Contego Medical, a Raleigh-based medical device firm that received FDA approval for two systems targeting neurovascular, coronary and peripheral vascular disease, has landed $22 million from 10 investors. Contego disclosed the funding in an SEC filing. In 2018, Conteo Medical received FDA approval for: The Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection.The “first” filter-based Integrated Embolic Protection (IEP) device, the Paladin Carotid PTA Balloon System. Contego CEO Ravish Sachar signed the filing. The...

Read More

Two Months until #SEBIO2018!!!

Posted by on Sep 19, 2018 in Uncategorized | 0 comments

Two Months until #SEBIO2018!!!

Register!!!  Make those hotel reservations!!! Please join us in Atlanta, Georgia, November 13-14, for our 20th Anniversary SEBIO Investor & Partnering Forum.

Read More

Trains, Bicycles, And Business Development

Posted by on May 31, 2018 in Uncategorized | 0 comments

It’s heresy to write this but it’s trains not bicycles that come to mind when describing our partnering strategy at Bicycle Therapeutics. We’re looking to speed Shinkansen-style towards our goal of being an integrated oncology company while monetizing the platform and building an engine for future growth in additional diseases. We can only do this by establishing partnerships both inside and outside of our core therapeutic area. Partnering outside of your core expertise can be challenging since you are pitching early-stage data from your lead therapy area, the relevance of which...

Read More

FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults

Posted by on Feb 15, 2018 in Uncategorized | 0 comments

The U.S. Food and Drug Administration today permitted marketing of the first blood test to evaluate mild traumatic brain injury (mTBI), commonly referred to as concussion, in adults. The FDA reviewed and authorized for marketing the Banyan Brain Trauma Indicator in fewer than 6 months as part of its Breakthrough Devices Program.  (The Banyan Brain Trauma Indicator is a product from Banyan Biomarkers, a spinout from the University of Florida in Gainesville, FL.) Most patients with a suspected head injury are examined using a neurological scale, called the 15-point Glasgow Coma Scale,...

Read More

Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities

Posted by on Jan 5, 2018 in Uncategorized | 0 comments

ATLANTA, GA. –  Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for rare inflammatory diseases, today announced the successful completion of a Series E financing led by Invus. Additional investors in the financing include Domain Associates, Lumira Capital, Masters Capital Management, RMI Partners and the Georgia Research Alliance Venture Fund.  In conjunction with the financing, Khalil Barrage, Managing Director at Invus, will join Celtaxsys’ board of directors. Celtaxsys’ lead candidate, once-daily oral acebilustat, is currently...

Read More

Corin USA expands headquarters

Posted by on Jul 12, 2017 in Uncategorized | 0 comments

TAMPA, FL. – Corin, a global manufacturer of orthopedic devices and high-tech solutions to improve surgical procedures, today announced that it will expand its US headquarters in Tampa. The company will add up to 100 new high-wage jobs in marketing, operations, sales and other administrative roles and invest $500,000 in its new offices by 2022. “We are fortunate to have such strong growth, which has enabled rapid expansion of our staff and facilities,” said Paul Berman, president of Corin USA. “Tampa has been and will continue to be a corridor of technological and...

Read More